A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia.

Trial Profile

A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2015

At a glance

  • Drugs Cytarabine; Mitoxantrone; Panobinostat
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Apr 2012 Planned End Date changed from 1 May 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.
    • 17 Apr 2012 Planned number of patients changed from 56 to 59 as reported by ClinicalTrials.gov.
    • 13 Dec 2011 Status changed from recruiting to completed, as presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top